Clinical Institute of Occupational Medicine, University Medical Center Ljubljana, Ljubljana, Slovenia.
Dis Markers. 2012;32(2):123-31. doi: 10.3233/DMA-2011-0866.
Soluble mesothelin-related peptides (SMRP) are a potential tumor marker for malignant mesothelioma. The aim of this study was to determine the differences in SMRP levels in patients with malignant mesothelioma before treatment and in various responses to treatment and to investigate whether SMRP level could be useful in evaluating tumor response to treatment. The study included patients with malignant mesothelioma treated at the Institute of Oncology Ljubljana between March 2007 and December 2009. Blood samples were collected before treatment and/or in various responses to treatment. SMRP levels were determined using ELISA assay based upon a combination of two monoclonal antibodies. Mann-Whitney test was used to determine the differences in SMRP levels in various responses to treatment. Median SMRP was 2.80 nmol/L (range 0.00-34.80) before treatment, 0.00 nmol/L (range 0.00-0.00) in complete response, 0.48 nmol/L (range 0.00-4.40) in partial response, 1.65 nmol/L (range 0.00-20.71) in stable disease and 7.15 nmol/L (range 0.44-31.56) in progressive disease. Pre-treatment SMRP levels were significantly higher than in stable disease, partial response and complete response (p=0.006), as were SMRP levels in progressive disease compared to stable disease, partial response and complete response (p< 0.001). Our findings suggest that SMRP may be a useful tumor marker for detecting the progression of malignant mesothelioma and evaluating tumor response to treatment.
可溶性间皮素相关肽 (SMRP) 是恶性间皮瘤的一种潜在肿瘤标志物。本研究旨在确定治疗前恶性间皮瘤患者、不同治疗反应者的 SMRP 水平差异，并探讨 SMRP 水平能否用于评估肿瘤对治疗的反应。该研究纳入了 2007 年 3 月至 2009 年 12 月在卢布尔雅那肿瘤研究所接受治疗的恶性间皮瘤患者。在治疗前及不同治疗反应时采集血样。采用基于两种单克隆抗体组合的 ELISA 检测法测定 SMRP 水平。采用 Mann-Whitney 检验比较不同治疗反应者的 SMRP 水平差异。治疗前 SMRP 中位数为 2.80 nmol/L（范围 0.00-34.80），完全缓解者为 0.00 nmol/L（范围 0.00-0.00），部分缓解者为 0.48 nmol/L（范围 0.00-4.40），疾病稳定者为 1.65 nmol/L（范围 0.00-20.71），疾病进展者为 7.15 nmol/L（范围 0.44-31.56）。治疗前 SMRP 水平明显高于疾病稳定者、部分缓解者和完全缓解者（p=0.006），疾病进展者也明显高于疾病稳定者、部分缓解者和完全缓解者（p<0.001）。我们的研究结果表明，SMRP 可能是一种有用的肿瘤标志物，用于检测恶性间皮瘤的进展和评估肿瘤对治疗的反应。
